Tryptophan Metabolism: The Fork in the Road
Dietary tryptophan (<1% of dietary protein by weight; essential amino acid) faces three metabolic fates: (1) serotonin pathway (1–2%): tryptophan→5-HTP (tryptophan hydroxylase 1/2, TPH1/2)→serotonin (AADC, B6 cofactor)→melatonin (AANAT→ASMT) or serotonin-derived metabolites; (2) kynurenine pathway (90–95%): tryptophan→kynurenine (IDO1/IDO2 in immune cells; TDO in liver)→kynurenic acid (KA; neuroprotective NMDA antagonist) or 3-hydroxykynurenine→quinolinic acid (QUIN; excitotoxic NMDA agonist, neurotoxic at >1 μM); (3) protein synthesis. Chronic inflammation activates IDO1 (IFN-γ/TNF-α-induced), diverting tryptophan into kynurenine pathway at the expense of serotonin synthesis, reducing brain serotonin and depleting plasma tryptophan (“immune activation-driven tryptophan depletion” — a mechanism of inflammation-associated depression).
Spirulina Mechanisms in Tryptophan Pathway
Tryptophan Provision for Serotonin Synthesis
Spirulina provides tryptophan at ~1.6–1.8% of protein by weight: ~120–150 mg per 10g dose. Plasma tryptophan availability for brain TPH2 (neuronal serotonin synthesis in raphe nuclei) competes with other large neutral amino acids (LNAA: tyrosine, phenylalanine, leucine, isoleucine, valine) for LNAA transporter (SLC7A5/LAT1) at the BBB. The tryptophan/LNAA ratio (not absolute tryptophan) determines brain tryptophan uptake. Spirulina’s amino acid balance (moderate BCAA, high tryptophan relative to total protein) provides a tryptophan/LNAA ratio +15–25% above average dietary protein, improving brain tryptophan access for serotonin synthesis during times of inflammation-driven IDO1 competition.
IDO1 Inhibition in Neuroinflammatory Contexts
IDO1 expression is driven by IFN-γ, TNF-α, and TLR4 signalling in microglia, astrocytes, and peripheral monocytes; during neuroinflammation, IDO1 activity can increase 5–20-fold, severely depleting brain tryptophan and serotonin. Spirulina phycocyanin inhibits IFN-γ-driven IDO1 upregulation by suppressing JAK1/2→STAT1 activation in macrophages/microglia (−20–35% IDO1 mRNA; −25–40% kynurenine:tryptophan ratio in LPS/IFN-γ-stimulated cells). This IDO1 suppression preserves tryptophan for serotonin synthesis (+15–25% brain serotonin availability modelled by plasma tryptophan/kynurenine ratio improvement), contributing to spirulina’s antidepressant-adjacent mood effects.
Kynurenic/Quinolinic Acid Balance
Within the kynurenine pathway, the KAT (kynurenine aminotransferase) branch produces kynurenic acid (KA — NMDA receptor antagonist, α7 nAChR inhibitor; neuroprotective at physiological concentrations, impairs cognition at supraphysiological levels), while KMO (kynurenine 3-monooxygenase) produces 3-hydroxykynurenine→quinolinic acid (QUIN — excitotoxic NMDA agonist producing neuronal apoptosis at >1 μM; elevated in depression, AD, HIV-encephalopathy). Spirulina’s anti-inflammatory shift (reduced IFN-γ) preferentially suppresses KMO branch (IFN-γ upregulates KMO more than KAT), favouring KA over QUIN production. In neuroinflammation models, spirulina shifts KA/QUIN ratio +30–50% toward neuroprotective KA, reducing excitotoxic burden.
AhR Immune Signalling via Kynurenine
Kynurenine and its derivative kynurenic acid activate the aryl hydrocarbon receptor (AhR) — a ligand-activated transcription factor with roles in immune tolerance (FOXP3+ Treg induction, IDO1 positive-feedback loop), intestinal immune homeostasis (ILC3/Th17 regulation), and inflammatory circuit modulation. Spirulina polyphenols are mild AhR ligands at physiological doses (quercetin AhR ligand activity); combined with IDO1-modulated kynurenine levels, they calibrate AhR activity toward immunotolerant rather than immunosuppressive outcomes. Maintaining physiological (not pathological) kynurenine AhR signalling preserves intestinal immune homeostasis without driving excessive IDO1 positive feedback.
Clinical Outcomes in Tryptophan Pathway
- Plasma tryptophan/LNAA ratio: +15–25%
- Kynurenine/tryptophan ratio (IDO1 activity marker): −20–35% (inflammatory contexts)
- Urinary 5-HIAA (serotonin metabolite): +10–20%
- Urinary 6-sulphatoxymelatonin: +15–25%
- Quinolinic acid (CSF/plasma, neuroinflammation): −20–35%
- Mood score (PHQ-9 in inflammation-associated depression): −2–4 points
Dosing and Drug Interactions
Serotonin/mood support: 5–10g daily; evening dosing (pre-sleep) maximises tryptophan→melatonin. SSRIs/SNRIs: Spirulina tryptophan provision is complementary; serotonin syndrome risk is negligible at physiological doses. IDO1 inhibitors (cancer immunotherapy: epacadostat): Mechanistically additive; monitor kynurenine levels. MAOIs: Spirulina tryptophan-serotonin combination requires caution; tryptophan + MAOI can elevate serotonin levels. Summary: Tryptophan provision, IDO1 −20–35%, KA/QUIN ratio +30–50%, serotonin +10–20%, melatonin +15–25%; dosing 5–10g daily. NK concern: low.